Education
About Us
Working with TipRanks
Follow Us
XORTX Therapeutics Inc (TSE:XRTX)
:XRTX
XRTX Stock Chart & Stats
C$0.78
C$0.05(2.94%)
At close: 4:00 PM EST
C$0.78
C$0.05(2.94%)
Day’s Range― - ―
52-Week RangeC$0.49 - C$1.97
Previous CloseN/A
Volume514.00
Average Volume (3M)11.08K
Market Cap
C$3.55M
Enterprise ValueC$277.58K
Total Cash (Recent Filing)C$1.19M
Total Debt (Recent Filing)C$51.11K
Price to Earnings (P/E)―
Beta0.94
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,962,218
10 Day Avg. Volume30,736
30 Day Avg. Volume11,079
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.28
Price to Sales (P/S)0.00
P/FCF Ratio-0.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Minimal DebtMinimal debt reduces solvency and refinancing risk for a development-stage biopharma reliant on financing rounds. Low leverage preserves strategic optionality to fund trials or partnerships without heavy interest burdens, supporting survival through multi-stage clinical programs.
Improving Cash Outflows And FCF TrendA sustained reduction in cash burn signals better cost control or more efficient development spending. If trends persist, the company will lengthen runway per financing round and reduce dilution risk, improving the ability to advance clinical programs toward value-inflection points.
Focused Pipeline Addressing Chronic Kidney DiseaseA focused therapeutic strategy in progressive kidney diseases targets a high unmet medical need and a clear regulatory/development pathway. Concentration on oxypurinol creates scientific coherence, aiding trial design, expertise accumulation, and potential partner interest in a structurally growing CKD market.
Bears Say
No Revenue And Persistent LossesAbsent any product revenue, the business relies entirely on financing to fund R&D. Continued operating losses indicate the company has not yet demonstrated commercial viability; this structural dependency raises execution and financing risk through development cycles.
Material Equity ErosionSharp decline in shareholders' equity reflects accumulated losses and prior financing dilution, reducing the company's buffer against adverse outcomes. A weakened equity base limits flexibility in raising non-dilutive capital and can constrain bargaining power with partners or acquirers.
Ongoing Cash Burn; Reliance On External FinancingPersistent negative operating and free cash flow means future progress hinges on successful financing or partnerships. Repeated funding rounds can dilute shareholders and divert management time, and market dislocation could hinder access to capital at acceptable terms.
XRTX FAQ
What was XORTX Therapeutics Inc’s price range in the past 12 months?
XORTX Therapeutics Inc lowest stock price was C$0.48 and its highest was C$1.97 in the past 12 months.
What is XORTX Therapeutics Inc’s market cap?
XORTX Therapeutics Inc’s market cap is C$3.55M.
When is XORTX Therapeutics Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were XORTX Therapeutics Inc’s earnings last quarter?
Currently, no data Available
Is XORTX Therapeutics Inc overvalued?
According to Wall Street analysts XORTX Therapeutics Inc’s price is currently Overvalued.
Does XORTX Therapeutics Inc pay dividends?
XORTX Therapeutics Inc does not currently pay dividends.
What is XORTX Therapeutics Inc’s EPS estimate?
XORTX Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XORTX Therapeutics Inc have?
XORTX Therapeutics Inc has 6,962,218 shares outstanding.
What happened to XORTX Therapeutics Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of XORTX Therapeutics Inc?
Currently, no hedge funds are holding shares in TSE:XRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
XORTX Therapeutics Inc
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
Technical Analysis
Aptose Biosciences
―
Kane Biotech
―
Quest Pharmatech
―
BioVaxys Technology
―
Doseology Sciences
―
Options Prices
Currently, No data available
---